Cargando…
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we investigated whether baseline serum levels of IL-6 can predict the treatment response of patients with advanc...
Autores principales: | Kang, Da Hyun, Park, Cheol-Kyu, Chung, Chaeuk, Oh, In-Jae, Kim, Young-Chul, Park, Dongil, Kim, Jinhyun, Kwon, Gye Cheol, Kwon, Insun, Sun, Pureum, Shin, Eui-Cheol, Lee, Jeong Eun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Immunologists
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327149/ https://www.ncbi.nlm.nih.gov/pubmed/32655975 http://dx.doi.org/10.4110/in.2020.20.e27 |
Ejemplares similares
-
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2021) -
Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer
por: Hong, Green, et al.
Publicado: (2022) -
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
por: Kim, Kyung Hwan, et al.
Publicado: (2020) -
Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators
por: Kwon, Minsuk, et al.
Publicado: (2018) -
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)